Report of Foreign Issuer (6-k)
21 Novembro 2019 - 7:01PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2019
Anchiano
Therapeutics Ltd.
(Translation of registrant’s name
into English)
1/3 High-Tech Village, Givat Ram, P.O.
Box 39264
Jerusalem, 9139102 Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Anchiano Therapeutics Ltd. (“Anchiano”)
is hereby filing its third quarter 2019 financial results (the “Financial Statements”) with the Securities and Exchange
Commission in anticipation of a significant shareholder filing its quarterly report with the Israel Securities Authority. Israeli
law requires the shareholder to include the Financial Statements due to the significance to that shareholder of its position in
Anchiano. The Financial Statements are attached hereto as Exhibit 99.1 and are incorporated herein by reference.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Anchiano Therapeutics Ltd.
|
|
|
|
By:
|
/s/ Dr. Frank G. Haluska
|
|
|
Dr. Frank G. Haluska
|
|
|
Chief Executive Officer
|
Dated November
21, 2019
Anchiano Therapeutics (NASDAQ:ANCN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Anchiano Therapeutics (NASDAQ:ANCN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Anchiano Therapeutics Ltd da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Anchiano Therapeutics Ltd.